159 related articles for article (PubMed ID: 31907961)
1. Venetoclax and arsenic showed synergistic anti-leukemia activity in vitro and in vivo for acute myeloid leukemia with the NPM1 mutation.
Zhu HH; Qian JJ; Sun WJ; You LS; Wang QQ; Naranmandura H; Jin J
Am J Hematol; 2020 Mar; 95(3):E55-E57. PubMed ID: 31907961
[No Abstract] [Full Text] [Related]
2. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
3. Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia.
Ren J; Huang J; Yang Z; Sun M; Yang J; Lin C; Jin F; Liu Y; Tang L; Hu J; Wei X; Chen X; Yuan Z; Yang Z; Chen Y; Zhang L
J Exp Clin Cancer Res; 2024 Jun; 43(1):176. PubMed ID: 38909249
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Tiong IS; Dillon R; Ivey A; Teh TC; Nguyen P; Cummings N; Taussig DC; Latif AL; Potter NE; Runglall M; Russell NH; Raj K; Schwarer AP; Fong CY; Grigg AP; Wei AH
Br J Haematol; 2021 Mar; 192(6):1026-1030. PubMed ID: 32458446
[TBL] [Abstract][Full Text] [Related]
5. Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.
Karjalainen R; Liu M; Kumar A; He L; Malani D; Parsons A; Kontro M; Kallioniemi O; Porkka K; Heckman CA
Leukemia; 2019 Oct; 33(10):2548-2553. PubMed ID: 31175323
[No Abstract] [Full Text] [Related]
6. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.
Carter BZ; Tao W; Mak PY; Ostermann LB; Mak D; McGeehan G; Ordentlich P; Andreeff M
Blood; 2021 Oct; 138(17):1637-1641. PubMed ID: 34232981
[No Abstract] [Full Text] [Related]
7. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
[TBL] [Abstract][Full Text] [Related]
8. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
Cathelin S; Sharon D; Subedi A; Cojocari D; Phillips DC; Leverson JD; MacBeth KJ; Nicolay B; Narayanaswamy R; Ronseaux S; Liu G; Chan SM
Leukemia; 2022 Mar; 36(3):869-872. PubMed ID: 34743189
[No Abstract] [Full Text] [Related]
9. More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine.
Aldoss I; Marcucci G
Chin Clin Oncol; 2019 Oct; 8(S1):S25. PubMed ID: 31684734
[No Abstract] [Full Text] [Related]
10. Embelin potentiates venetoclax-induced apoptosis in acute myeloid leukemia cells.
Reis-Silva CSM; Branco PC; Lima K; Silva FL; Moreno PRH; Guallar V; Costa-Lotufo LV; Machado-Neto JA
Toxicol In Vitro; 2021 Oct; 76():105207. PubMed ID: 34216723
[TBL] [Abstract][Full Text] [Related]
11. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.
Jiménez-Vicente C; Martínez-Roca A; Pomares H; Castaño-Diez S; Guijarro F; López-Guerra M; Bataller A; Esteban D; Cortés-Bullich A; Pérez-Valencia AI; Guardia-Torrelles A; Zugasti I; Rovira M; Fernández-Avilés F; Colomer D; Arnan M; Díaz-Beyá M; Esteve J
Leuk Res; 2023 Dec; 135():107403. PubMed ID: 37837718
[No Abstract] [Full Text] [Related]
13. Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(
Florean C; Kim KR; Schnekenburger M; Kim HJ; Moriou C; Debitus C; Dicato M; Al-Mourabit A; Han BW; Diederich M
Mar Drugs; 2018 Dec; 16(12):. PubMed ID: 30572618
[TBL] [Abstract][Full Text] [Related]
14. Two novel NPM1 mutations in an acute myeloid leukemia patient transformed from primary myelofibrosis.
Park SH; Chi HS; Shim H; Jang S; Park CJ
Int J Lab Hematol; 2013 Feb; 35(1):e1-3. PubMed ID: 22978565
[No Abstract] [Full Text] [Related]
15. Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia.
Wang D; He J; Liu S; Zhang H; Tang D; Chen P; Yang M
Cancer Lett; 2024 Jul; 593():216970. PubMed ID: 38763475
[TBL] [Abstract][Full Text] [Related]
16. The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.
Lim B; Yoo D; Chun Y; Go A; Cho KJ; Choi D; Jung ME; Lee HY; Boohaker RJ; Lee JS; Jung D; Choi G
Blood Cancer J; 2022 Apr; 12(4):57. PubMed ID: 35410412
[No Abstract] [Full Text] [Related]
17. Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?
Pollyea DA; Jordan CT
Curr Opin Hematol; 2019 Mar; 26(2):71-76. PubMed ID: 30652974
[TBL] [Abstract][Full Text] [Related]
18. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
19. DNA damage corrects the aberrant cytoplasmic localisation of nucleophosmin in NPM1 mutated acute myeloid leukaemia.
Bailey GD; Qutob HMH; Akhtar A; Russell NH; Seedhouse CH
Br J Haematol; 2019 Jul; 186(2):343-347. PubMed ID: 30836427
[No Abstract] [Full Text] [Related]
20. Venetoclax induced complete remission in extramedullary relapse of AML co-harboring
Pan W; Zhao X; Shi W; Jiang Z; Xiao H
Leuk Lymphoma; 2020 Nov; 61(11):2756-2759. PubMed ID: 33167720
[No Abstract] [Full Text] [Related]
[Next] [New Search]